// Social Icons

Update from the USANZ ASM Convenor - Declan Murphy

Only five weeks to go to the USANZ 2023 ASM! And this week we are looking at some of the many prostate cancer highlights in the Program. We are covering the entirety of prostate cancer, from early detection to castration-resistant disease, and focussing on the hottest topics which will interest delegates.

For example, did you know that 2023 is about to herald widespread access to AR pathway inhibitors for patients with metastatic hormone-sensitive prostate cancer (mHSPC)?? At least in Australia, and hopefully in New Zealand at some stage soon. These oral drugs (such as apalutamide, enzalutamide, darolutamide and abiraterone), have been shown to significantly improve overall survival, but have not been funded in either of these islands for mHSPC. The upcoming changes mean that instead of just starting your newly-diagnosed mHSPC patient on ADT alone, or referring for upfront chemotherapy, you will be able to start on drugs such as apalutamide and enzalutamide, without any costs to the patient. To help educate ourselves on all of this, we present two dedicated workshops on Saturday focusing on the use of these drugs both in the newly diagnosed metastatic patient, and in the nonmetastatic castration resistant patient. Joseph Ischia, Renu Eapen, Arun Azad and Derya Tilki are co-Chairing each workshop, and have put together excellent programs. This will be a very important topic for urology going forward so we strongly encourage you to book in to one or both workshops if this is an area you are interested in.

Another fantastic prostate cancer workshop, co-chaired by Jeremy Grummet and Lih-Ming Wong, focuses on imaging in prostate cancer. Australia and New Zealand have advanced experience in MRI and PSMA PET/CT, and this workshop will bring you the very latest across these modalities. Sure to fill up quickly.

Our International Faculty include some very well-known key opinion leaders in prostate cancer including Professor Caroline Moore (University College London), Professor Derya Tilke (Martini-Klinik, Hamburg), and Professor Kirsten Green (University of Virginia). These three fantastic speakers pop up throughout the program and I encourage you to have a look through and try not to miss their varied contributions. Having perspectives from the US, UK, and mainland Europe, mixed in with our own advanced experience here in Australia and New Zealand, should provide some very lively prostate cancer discussions indeed.

Early bird registration closes 3rd February 2023. See you next month!